THE ROLE OF HYPOCOMPLEMENTEMIA AND LOW ERYTHROCYTE COMPLEMENT RECEPTOR TYPE-1 NUMBERS IN DETERMINING ABNORMAL IMMUNE-COMPLEX CLEARANCE IN HUMANS
- 1 March 1989
- journal article
- research article
- Vol. 75 (3) , 329-335
Abstract
Defective clearance of immune complexes (IC) may contribute to the pathogenesis of diseases such as SLE. We studied the effect of hypocomplementaemia and the influence of erythrocyte complement receptor type 1 (CR1, CD35) number on the clearance of radiolabelled tetanus toxoid (TT)-anti-TT IC from the circulation. These were injected intravenously into 9 normal subjects and 15 patients with diseases characterized by IC formation and/or hypocomplementaemia, including 2 with hereditary complement deficiency. IC were found to bind to erythrocyte CR1 in a complement-dependent manner and their degree of uptake was directly correlated with CR1 numbers. Two phases of IC clearance were identified. The first was rapid, occurring within 1 min. Since this phase might represent inappropriate deposition of IC in target organs we called it trapping. It was seen predominantly in subjects with low CR1, low complement, and low binding of complexes to red cells. The second phase was monoexponential with a mean elimination rate of 14.1%/min; it was inversely correlated with CR1 numbers and binding of complexes to red cells. In a second study each individual was injected with IC bound to autologous erythrocytes in vitro using normal serum so that the effects of complement deficiency were eliminated. Up to 81.4% of these bound IC were released in vivo from erythrocytes in 1 min, and the proportion was inversely correlated with CR1 numbers. Only five patients showed trapping, and these had low CR1 numbers and high percentage release of IC. The second phase of elimination was inversely correlated with CR1 numbers and the proportion of IC remaining bound to red cells at 1 min. The two complement-deficient patients had normal CR1: when IC were injected, trapping and very fast clearance rates were observed; however complexes that had been opsonized and bound to erythrocytes were cleared at a slower rate without evidence for trapping. These studies show that complement and erythrocyte CR1 may determine the physiological clearance of certain types of IC and suggest that this system may function abnormally when CR1 number of complement function are reduced.This publication has 19 references indexed in Scilit:
- ABNORMAL CLEARANCE OF SOLUBLE AGGREGATES OF HUMAN IMMUNOGLOBULIN-G IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS1988
- The Role of Complement and Its Receptor in the Elimination of Immune ComplexesNew England Journal of Medicine, 1986
- Differential binding of immunoglobulin A and immunoglobulin G1 immune complexes to primate erythrocytes in vivo. Immunoglobulin A immune complexes bind less well to erythrocytes and are preferentially deposited in glomeruli.Journal of Clinical Investigation, 1986
- Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.The Journal of Immunology, 1985
- Complement depletion accelerates the clearance of immune complexes from the circulation of primates.Journal of Clinical Investigation, 1984
- Immunoglobulin G Fc Receptor-Mediated Clearance in Autoimmune DiseasesAnnals of Internal Medicine, 1983
- Primate erythrocyte-immune complex-clearing mechanism.Journal of Clinical Investigation, 1983
- The 1982 revised criteria for the classification of systemic lupus erythematosusArthritis & Rheumatism, 1982
- Clearance of circulating DNA-anti-DNA immune complexes in mice.The Journal of Experimental Medicine, 1982
- Saturation of the Reticuloendothelial System with Soluble Immune ComplexesThe Journal of Immunology, 1974